HOUSTON & MILAN--(BUSINESS WIRE)--Sibylla Biotech and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration agreement to discover and develop novel small-molecule cancer therapies known as Folding Interfering Degraders (FIDs), which disrupt the proper folding of target proteins and lead to their degradation.
Ori Biotech, a leader in cell and gene therapy (CGT) manufacturing technologies, and the Cell Therapy Manufacturing Center (CTMC), a joint venture between National Resilience Inc. and MD Anderson Cancer Center, have entered a collaborative partnership to develop industrial manufacturing processes for cell therapies.
VANCOUVER, British Columbia & HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Virogin Biotech, a clinical-stage biotech company, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.
A Littleton, CO, sleep apnea medtech was supposed to hold its Q2 earnings call on Aug. 15, then Aug. 22 and now maybe not for weeks. It could take “several weeks” before Vivos Therapeutics resolves issues with a “technical reevaluation of our revenue recognition policy,” the company said Monday after the closing bell. Vivos CEO Kirk Huntsman said the delay is “unrelated to the overall health” of the company.
Erasca, a company whose mission is to erase cancer, announced the expansion of its pipeline of precision oncology therapies via two exclusive, worldwide agreements directed at targeting critical upstream and downstream nodes in the RAS/MAPK signaling cascade, one of the most frequently mutated oncogenic pathways in cancer. ERAS-601, a potential best-in-class inhibitor of the Src homology region 2 domain-containing phosphatase-2 (SHP2), was licensed from NiKang Therapeutics, Inc. ERAS-007, a potential best-in-class inhibitor of the extracellular signal-regulated kinase (ERK), the most distal node of the RAS/MAPK pathway, was acquired from ASN Product Development, Inc., a wholly owned subsidiary of Asana BioSciences, LLC.
HOUSTON and SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted...
HOUSTON, June 16, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. (Invectys), The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), a joint venture between MD Anderson and National Resilience, Inc., today announced a strategic collaboration to jointly develop a reliable, compliant and scalable process for human leukocyte antigen (HLA)-G targeted chimeric antigen receptor (CAR) T cell therapy for solid tumors.
The University of Texas MD Anderson Cancer Center and contract biologic manufacturer Resilience are cracking open a new partnership, seeking to accelerate the development and manufacturing of cell therapies for cancer patients.
Alpha Tau Medical Ltd. (Alpha Tau), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced that it has signed a sponsored research agreement with investigators at The University of Texas MD Anderson Cancer Center (MD Anderson) to evaluate potential immune stimulation by combining Alpha DaRT with DNA-repair inhibitors and immune checkpoint inhibitors for the treatment of breast tumours.
SAN FRANCISCO and HOUSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Yingli Pharma US, Inc. (the “Company” or “Yingli”), a biotechnology company developing innovative small molecules, and The University of Texas MD Anderson Cancer Center today announced a strategic alliance to advance several oncology programs from preclinical discovery through clinical development.